<DOC>
	<DOC>NCT02258581</DOC>
	<brief_summary>This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB).</brief_summary>
	<brief_title>Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Must have participated in a Gileadsponsored chronic hepatitis B (CHB) study no more than 120 days prior to Baseline (Day 1), except for participants from previous Gileadsponsored study number GSUS1740149, who will have up to one year from their last visit in that protocol. Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures Must be willing and able to comply with the visit schedule and study requirements Must have documented HBV DNA &lt; 2,000 IU/mL at time of screening visit, which shall occur no later than 1 year post last study visit in GSUS1740149 Must have documented hepatitis B surface antigen (HBsAg) negative status anytime during participation in GSUS1740149 regardless of ongoing HBV treatment Key Patient participating or planning to participate in another clinical study with an investigational agent History of clinicallysignificant illness or any other major medical disorder that may interfere with followup, assessments or compliance with the protocol Believed by the Study Investigator to be inappropriate for study participation for any reason not otherwise listed Received TDF monotherapy either as part of GSUS1740149 Arm C (TDF monotherapy arm) or for TDF retreatment, and have taken any HBV antiviral therapy since completion of GSUS1740149 Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>